Dr. Mervyn Turner has over 25 years of experience in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets, strategy development and implementation. He is recognized for his deep industry perspective and for his global connections within the pharmaceuticals sector, biotech, and venture capital. In his last role prior to his retirement from Merck & Co. Inc., he was the company’s first Chief Strategy Officer, and drove strategy planning and resource planning discussions. He also worked with the research division, the commercial organization and the manufacturing division to develop a coherent, overarching strategy for Merck & Co. Inc.’s investments in the emerging markets. Prior to that, he led the transformation of Merck & Co., Inc. from an inward-facing to an outward looking organization as head of World Wide Licensing & External Research. He was personally involved in more than 200 strategic transactions, including mergers and acquisitions. Before that, he was the Site Head for both Merck & Co. Inc.’s largest R&D facility (Rahway, NJ), and it’s most productive labs (Merck Frosst, Canada). In that role, he oversaw the introduction of multiple development candidates. Dr. Turner has published over 80 articles in peer reviewed journals.